Table 3.
Enzyme | Upstream Regulator(s) | Downstream Pathways | Cancer Tissue/Cell Line | Effect * | |
---|---|---|---|---|---|
ALG3 | TGF-β receptor 2 | Breast | Stemness, radioresistance | [94] | |
Heat shock factor 2 | Breast | Progression | [95] | ||
miR-98-5p | Non-small cell lung | Progression | [5] | ||
B3GNT3 | RhoA/RAC1 | Endometrial | Progression | [61] | |
miR-149-5p | Lung | Progression | [62] | ||
EGFR/PD-L1 | Lung | Immune escape | [66] | ||
EGF/PD1-PD-L1 | Breast | Immune escape | [65] | ||
B3GNT5 | lncRNA MIR44352HG/miR1365p | Liver | Progression | [96] | |
B3GNT7 | Promoter methylation | Colorectal | Inhibition ** | [57] | |
B4GALT3 | lncRNA DANCR/miR-338-3p | Neuroblastoma | Progression | [70] | |
β1-integrins | Neuroblastoma | Progression | [71] | ||
miR-27a | β1-integrins | Cervical | Progression | [73] | |
β1-integrins | Colorectal | Inhibition | [74] | ||
B4GALT5 | Wnt/β-catenin | Breast | Stemness | [44] | |
Circ_0009910/miR-491-5p | PI3K/AKT | Acute myeloid leukemia | Progression | [97] | |
B4GALNT1 | JNK/c-Jun/Slug | Lung | Progression | [47] | |
EGFR | breast | Stemness | [50] | ||
β1 integrins/FAK/SRC/ERK | Glioblastoma, lung, kidney | Progression | [52] | ||
GM2/GD2 | Melanoma | Angiogenesis, progression | [51] | ||
GALNT2 | IGF-R1 | Neuroblastoma | Inhibition | [98] | |
Met | Gastric | Inhibition | [18] | ||
EGFR | Liver | Inhibition | [17] | ||
EGFR/AKT | Oral squamous | Progression | [12] | ||
EGFR/PI3K/AKT/mTOR | Glioma | Progression | [13] | ||
Notch/Hes1-PTEN-PI3K/AKT | Lung | Progression | [15] | ||
GALNT10 | DLGAP1-AS2/miR-505 | Bile ducts | Progression | [20] | |
HNF4/miR-122 | Liver | Progression | [21] | ||
Histone methylation/ZBTB2 | Ovary | Stemness | [99] | ||
FUT7 | EGFR/AKT/mTOR | Lung | Progression | [88] | |
Promoter methylation | Bladder | Progression | [90] | ||
EGFR | Thyroid | Progression | [91] | ||
POFUT1 | Notch | Liver | Progression | [31,32] | |
Colorectal | [28,29] | ||||
Glioblastoma | [34] | ||||
ST3GAL4 | Met, RON | Gastric | Progression | [85,100,101] | |
Promoter methylation/GATA2 | Ovary, Breast | Progression | [102,103] | ||
miR-370 | Colorectal | Adhesion | [104] | ||
ST6GALNAC4 | miR-429 | Thyroid | Progression | [83] |
* The indicated effect is positively related to the expression of the indicated glycosyltransferase. ** Inhibition indicates attenuation of the neoplastic phenotype.